Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Accumulated Expenses (2023 - 2025)

Monte Rosa Therapeutics' Accumulated Expenses history spans 3 years, with the latest figure at $3.8 million for Q1 2025.

  • For Q1 2025, Accumulated Expenses rose 8.53% year-over-year to $3.8 million; the TTM value through Mar 2025 reached $3.8 million, up 8.53%, while the annual FY2024 figure was $7.2 million, 35.14% up from the prior year.
  • Accumulated Expenses reached $3.8 million in Q1 2025 per GLUE's latest filing, down from $7.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $7.2 million in Q4 2024 to a low of $3.2 million in Q1 2023.
  • Average Accumulated Expenses over 3 years is $5.1 million, with a median of $5.1 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 35.14% in 2024, then grew 8.53% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $5.3 million in 2023, then surged by 35.14% to $7.2 million in 2024, then crashed by 46.73% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Accumulated Expenses are $3.8 million (Q1 2025), $7.2 million (Q4 2024), and $6.7 million (Q3 2024).